The stock of PDS Biotechnology Corporation (NASDAQ:PDSB) increased by $0.05 on Friday to finish at $4.85, up 1.15 percent. The last five days have seen an average of 500,420 shares of common stock traded. 1 time new highs were reached in the current year, with a fall of -$8.35. The average number of shares traded over the last 20 days was 549,900, while the average volume over the last 50 days totaled 1,002,878.
PDSB stock dropped -6.37% since last month. On 08/11/23, the company’s shares reached a one-month low of $4.62. The stock touched a high of $13.65 on 01/03/23, after rallying from a low of $2.89 in 52 weeks. The price of PDSB stock has declined by -63.26% or -$8.35 this year, reaching a new high 1 time. Still, the stock price is down -64.47% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the recent quarter, PDS Biotechnology Corporation’s quick ratio was 16.50, while its current ratio was 16.50, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the recent quarter is 0.57, and the total debt to equity ratio is 0.57. Based on annual data, it had gross profit of $1.32 million and revenue of $41.67 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PDSB’s return on assets (ROA) during the last 12 months has been -60.90%. In the meantime, the return on equity (ROE) for the last 12 months was -91.60%.
Earnings Surprise
A lower net income was reported in the quarter under review than the previous quarter. EBITDA was -$9.29 million for the quarter. At the end of PDS Biotechnology Corporation’s most recent quarter, its liabilities totaled 27.44 million, while its total debt was $23.51 million. Equity owned by shareholders amounts to $30.82 million.
Technical Picture
Here’s a quick look at PDS Biotechnology Corporation’s (PDSB) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 37.14%, suggesting the stock is Neutral, with a 76.50% historical volatility rate.
The stochastic %K and %D were 21.09% and 31.76% respectively, while the average true range (ATR) was 0.39. Based on the 14-day stochastic reading of 16.85%, the RSI (14) reading is 40.50%. On the 9-day MACD Oscillator, the stock is at -0.37, and the 14-day reading is at -0.35.
Analyst Ratings
In its analyst report released on November 01, 2022, B. Riley Securities began covering PDS Biotechnology Corporation (NASDAQ: PDSB). The stock was rated as a Buy by the brokerage firm. Analysts have assigned PDS Biotechnology Corporation (PDSB) an Buy rating. PDSB is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 7 others recommend it as a buy.
What is PDSB’s price target for the next 12 months?
The current consensus forecast for the stock is between $14.00 and $25.00, with a median target price of $18.00. In analyzing these forecasts, the average price target given by analysts for PDS Biotechnology Corporation (PDSB) is $19.29.
